May 19, 2020

Alan Jones' Show to Continue Without Ads

Business
Australia
Macquarie Radio Network
Julia Gillard
Bizclik Editor
2 min
Alan Jones' Show to Continue Without Ads

Radio broadcaster Alan Jones’ weekly breakfast show will run without advertising, a decision reached by 2GB as numerous sponsors continue to cancel their promotions – costing the station $80,000 a day – in light of the recent controversy surrounding Jones’ name.

2GB, the station on which Jones broadcasts, has reportedly pulled all advertising from the program in an effort to protect these businesses from the “cyber bullying” campaign launched as a result of Jones’ proclamation that Prime Minister Julia Gillard’s father had “died of shame” over her “lies” two weeks ago.

 "The nature, tone and volume of the reaction to Jones's remarks, and in particular the threats being made through social media to companies advertising on Jones's program and the disruption being caused to their businesses, have made it necessary for MRN [Macquarie Radio Network] to call 'time out',” said Macquarie executive chairman Russell Tate to Perth Now.

Online petitions and Facebook groups calling for Jones’ sacking have been popping up and gaining thousands of online supporters. Many small businesses have reportedly been threatened to pull their support from the program as well.

The most prominent advertiser to pull out has been Mercedes-Benz, who not only ceased their advertising with 2GB, but also repossessed Jones’ $250,000 sponsored sedan. Arriving to work this morning in a silver Lexus, Jones has reportedly lashed out at Mercedes-Benz corporate communications manager David McCarthy for the company’s actions, calling him a ‘gutless wonder.’

Twenty-two year old Sydney student Nic Lochner, who started the Change.org petition “2GB and Advertisers: Immediately cease association with Alan Joes over ‘died of shame’ comment,” has called the decision to cut advertising from the breakfast show “a ploy to short-circuit the controversy.”

"They don’t address the two issues at play here - that Alan Jones is a serial offender when it comes to hate speech, and that the response from the Australian public has been a genuine groundswell of disgust to this appalling kind of behavior,” said Lochner.

"This is not about cyber-bullying. It is about customers exercising their right to call companies to account about the kind of behaviour they want to see in Australian society.

"This campaign has been about calling for civility and decency in public debate and we have gone to great strides to ensure that discourse is conducted appropriately.”

Share article

Jun 13, 2021

Seo JungJin: Who is EY’s World Entrepreneur of 2021?

EY
entrepreneurs
Leadership
celltrion
Kate Birch
3 min
From just US$45,000 capital in 2003 to a world-leading biopharma giant with revenues of US$1.69bn today, Seo JungJin is crowned EY World Entrepreneur 2021

Seo JungJin, founder of biopharma firm Celltrion, which most recently developed an antibody treatment for COVID-19, has been named the EY World Entrepreneur of the Year 2021, becoming the first South Korean in the award’s 21-year history.

Regarded as one of the world’s most prestigious business awards program for entrepreneurs, the EY Entrepreneur of the Year celebrates visionary and innovative leaders from across 60 countries who are transforming the world and fostering growth.

JungJin, who is now honoroary chairman of Celltrion Group, was up against a worthy cast of entrepreneurial competitors, taking the crown from among 45 award winners across 38 countries and territories.

Speaking during the virtual event, JungJin described his own interpretation of entrepreneurship as something that brings together “a group of people toward a common vision, embracing challenges as opportunities and committing oneself to contribute to the greater good”.

Why was JungJin crowned King Entrepreneur?

A South Korean native and now 63 years of age, JungJin founded biopharmaceutical firm Celltrion in 2003. In the nearly two decades since its founding, Celltrion has lived up to its goal of advancing health and welfare for all by developing ground-breaking drugs to treat autoimmune disease, various forms of cancer and, most recently, COVID-19.

The company, which JungJin started with just US$45,000 and five of his colleagues, has since growth to more than 2,1000 employees with sales permits in more than 90 countries and revenues exceeding US$1.69bn.

According to the panel, JungJin’s story is a shining example of the power of an unstoppable entrepreneur to change the world with the pandel moved by both his incredible story and his purpose-driven leadership, innovative mindset and entrepreneurial spirit.

Described by the chair of the EY judging panel Rosaleen Blair as “representing everything an unstoppable should be” from taking on the world’s biggest health care challenges to consistently creating long-term value for his company, JungJin’s story is one of incredible tenacity and perseverance that the judging panel felt most represented the entrepreneurial spirit.

“He’s taken breathtaking risks, both personal and professional, to found Celltrion and grow it into one of the world’s leading biopharmaceutical companies,” says Stasia Mitchell, EY Global Entrepreneurship Leader. “His passion for creating affordable, life-saving health care and flair for tackling global problems has led to many treatments that have helped millions of people worldwide and was especially evident this past year through the creation of a COVID-19 antibody treatment.”

How did JungJin get there?

JungJin's entrepreneurial journey started at an early age when he worked as a taxi driver to get himself through Konkuk University in Seoul, South Korea. After studying industrial engineering, he rose through the ranks of Daewoo Motor Co. before losing his job amid the carmaker’s financial troubles following the 1997 Asian economic crisis.

Following this, JungJin started collaborating with colleagues to explore business opportunities in different industries, though none delivered lasting success. The turning point came after he attended a talk hosted by renowned scholars, which inspired him to focus on the biopharmaceutical sector.

And so he founded Celltrion with just US$45,000 of his savings. The launch of Remsima, credited with being the world's first antibody biosimilar, quickly moved Celltrion up the ranks of the country's fairly underdeveloped pharmaceutical sector. Celltrion followed this success with the launch of drugs for breast cancer and lymphoma that today are being used worldwide.

With ambitions to be the world’s first in different areas, Celltrion has pioneered numerous uncharted areas to great success over the past two decades, most recently responding to the global pandemic by successfully developing an antibody treatment for COVID-19 and working to ensure a timely supply of the safe and effective treatment.

“When I first started, my vision was to help patients gain access to safe, effective and affordable medicines and thereby enhance the quality of people’s lives,” explains JungJin. “The success of Celltrion has enabled me to expand on this while finding new ways to fuel my entrepreneurial drive.”

 

Share article